ICARE is finding and evaluating new treatment approaches every day --- that could extend your life! Register, get our newsletter, and possibly join our academic collaboration to help your doctor and you make the next best therapeutic decision possible.
Begin Your Journey: Step 1 Register
Complete a simple online form to register with us and Join the I-Team network. Receive a welcome email with links to the current standard of care information and clinical trials from us about your specific cancer.
- Join Your Investigative-Team (I-Team) Network as a Patient, Doctor, Researcher, Volunteer, Advocate, and/or Employee
- Become a Recipient of our Options Newsletter
Begin Your Journey: Step 2 Donate
Help ICARE build the I-Team network in your cancer type that harnesses the global intellect (including ideas, therapies, and technologies) and delivers it locally to you and your doctor. Click on the I-Team Support Programs and select your cancer type.
- Donate Funds to Your I-Team
- Donate Therapeutic Knowledge to the Network
- Donate Tumor Tissues Through Your I-Team Network
Begin Your Journey: Step 3 Participate
Actively participate in your I-Team’s regular online research meetings. Collaborate with physicians and scientists around the world to discover more and better therapeutic options with the ultimate goal of improving each patient’s chances of survival. Link to information to facilitate the inclusion of your living tumor tissue into the I-Team process.
- Digital and/or In-Person Meetings with Physicians and Scientists
- Discover Even More Therapeutic Options
- Identify Targeted Treatments with Your Living Tumor Tissue
We are sorry about your diagnosis but we are pleased that you have found the International Cancer Alliance for Research and Education (ICARE) — a 501(3)(c) tax exempt public charity since 1985. In 2010, ICARE.org began to focus its programs on building and funding local and international medical academic research teams (I-TEAMS) that can support decisions of individual patients and their doctors — rather than on just providing research information to the general public.
Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed Friday, April 14, 2017 Small, phase one trial of a dendritic cell vaccine supports further study in...
Dr. Ronald Levy’s Stanford Laboratory recently published the success of a new immunotherapy approach to treatment of advanced cancers. Here is the abstract from the...
Dr. Brian Czerniecki’s Her 2 Breast Cancer Vaccine prevents recurrence over 7 years in Her 2 positive/ER negative patients : See story at https://www.penniesinaction.org/testimonials.html – Here...